Case Report
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 26, 2021; 9(27): 8220-8225
Published online Sep 26, 2021. doi: 10.12998/wjcc.v9.i27.8220
Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benefits from both afatinib and osimertinib: A case report
Yao Zhang, Ji-Qiao Shen, Lin Shao, Yan Chen, Lei Lei, Jia-Lei Wang
Yao Zhang, Ji-Qiao Shen, Jia-Lei Wang, Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
Yao Zhang, Ji-Qiao Shen, Jia-Lei Wang, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
Yao Zhang, Ji-Qiao Shen, Jia-Lei Wang, Institute of Thoracic Oncology, Fudan University, Shanghai 200032, China
Lin Shao, Yan Chen, Lei Lei, Burning Rock Biotech, Guangzhou 510300, Guangdong Province, China
Author contributions: Zhang Y and Wang JL contributed to the conception and design; Zhang Y and Shen JQ contributed to the provision of study materials; Zhang Y, Shen JQ, Chen Y, and Lei L contributed to collection and assembly of the data; Chen Y and Lei L contributed to the experiment methods; Shao L wrote the manuscript; all authors contributed to the revision and final approval of the manuscript.
Informed consent statement: Written informed consent was obtained from the patient for publication of this case report and any accompanying images in an anonymised manner.
Conflict-of-interest statement: The authors declare that there is no conflict of interest to report.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jia-Lei Wang, MD, Chief Physician, Department of Medical Oncology, Fudan University Shanghai Cancer Center, No. 270 Dongan Road, Shanghai 200032, China. m18017312369@163.com
Received: May 8, 2021
Peer-review started: May 8, 2021
First decision: June 5, 2021
Revised: June 17, 2021
Accepted: July 5, 2021
Article in press: July 5, 2021
Published online: September 26, 2021
Processing time: 131 Days and 5.7 Hours
Core Tip

Core Tip: Our case revealed that both afatinib and the osimertinib + bevacizumab combination demonstrated clinical efficacy in a non-small cell lung cancer patient harboring a rare epidermal growth factor receptor (EGFR) L833F-L861Q compound mutation. The results provide more options for the clinical management of patients with rare EGFR compound mutations.